FDA
Orders where directed actors are tied to FDA · 5 in Trump 47 · 10 all terms.
Roles directed
Orders
5 shown · Trump 47
Supporting America's Ranchers
This executive order directs multiple agencies to review and recommend changes to regulations affecting ranchers, with specific focus on wolf delisting under the Endangered Species Act, mandatory country-of-origin labeling for beef, and streamlining depredation compensation. It requires reports within 90 days and sets up potential regulatory and legislative actions to support domestic cattle producers.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs federal agencies to accelerate research, regulatory review, and patient access to psychedelic drugs (including ibogaine compounds) for treating serious mental illness and reducing suicide rates. It creates FDA priority vouchers for breakthrough-designated psychedelics, establishes Right to Try access pathways, funds state-federal collaboration through ARPA-H, mandates interagency data sharing with VA, and requires timely DEA rescheduling of approved psychedelic products.
Addressing Addiction Through the Great American Recovery Initiative
This executive order establishes the White House Great American Recovery Initiative, co-chaired by the Secretary of HHS and a Senior Advisor for Addiction Recovery, to coordinate federal response to substance use disorder. The Initiative brings together 15+ officials across cabinet departments and agencies to recommend steps for aligning federal programs, increasing treatment access, and integrating addiction services across health, criminal justice, workforce, education, and housing systems.
Increasing Medical Marijuana and Cannabidiol Research
This executive order directs the Attorney General to expedite rescheduling marijuana from Schedule I to Schedule III of the Controlled Substances Act to facilitate medical research. It also directs multiple health agencies to develop research methods using real-world evidence for medical marijuana and hemp-derived CBD products, and tasks White House legislative staff with working Congress to update statutory definitions for hemp-derived cannabinoids.
Regulatory Relief To Promote Domestic Production of Critical Medicines
This executive order directs federal agencies to streamline regulatory and permitting processes for domestic pharmaceutical manufacturing, with specific actions by FDA, EPA, Army Corps of Engineers, and OMB. It also mandates increased inspections and fees on foreign manufacturing facilities and requires public disclosure of foreign inspection data, aiming to reduce domestic facility construction timelines from 5-10 years and shift production back to the United States.